https://doi.org/10.4081/aiua.2024.12956
Healing of Peyronie's disease after multimodal antioxidant treatment. A case series
Published: October 29, 2024
Abstract Views: 50
PDF: 34
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Introduction: Peyronie’s disease (PD) is characterized by fibrosis of the penile tunica albuginea. Conservative treatment options may involve oral and/or injectable medications.
Materials and methods: This case series includes four patients with PD in the first phase. The diagnosis of PD included a medical history; penile palpation; a physical examination of the penis, documenting penile deformity (Kelâmi method); penile dynamic Doppler ultrasound (PDDU) + elastography, measuring the plaque and calculating its volume (cm3), and the deformation index (strain ratio); and the completion of the following questionnaires: IIEF to assess erectile function, VAS to assess pain, and Peyronie's Disease Questionnaire (PDQ) symptom bother to evaluate the psychosexual impact of the disease. Diagnostic follow-up evaluations were conducted before and every 6-12 months throughout the conservative treatment. The four patients were treated at our andrology clinic between January 2019 and November 2023. Our treatment included the following: bilberry, propolis, ginkgo biloba, silymarin, L-carnitine, coenzime Q-10, Boswellia, superoxide dismutase, vitamin E, vitamin C, topical diclofenac gel, propolis cream, and perilesional penile injections with pentoxifylline for cases involving penile plaques with volumes of > 0.100 cm3.
Results: Complete resorption of the PD plaque after treatment occurred in all cases. The disappearance of Peyronie's plaque occurred over a period ranging from 18 to 36 months, in relation to the volume of the plaque.
Conclusions: Despite the limited sample size in our study, these patients verifiably achieved the complete resorption of the affected disease area. Our results will provide useful insights for uroandrological clinical practice. Nevertheless, randomized controlled trials with a larger number of PD patients are needed to demonstrate the effectiveness of multimodal antioxidant treatment.
Bias WB, Nyberg LM Jr, Hochberg MC, et al. Peyronie’s disease: A newly recognized autosomal-dominant trait. Am J Med Genet. 1982;12:227-235.
DOI: https://doi.org/10.1002/ajmg.1320120213
Schwarzer U, Sommer F, Klotz T, et al. The prevalence of Peyronie’s disease: Results of a large survey. BJU Int. 2001; 88:727-730.
DOI: https://doi.org/10.1046/j.1464-4096.2001.02436.x
Rhoden EL, Teloken C, Ting HY, et al. Prevalence of Peyronie’s disease in men over 50-y-old from Southern Brazil. Int J Impot. Res. 2001; 13:291-293.
DOI: https://doi.org/10.1038/sj.ijir.3900727
La Pera G, Pescatori ES, Calabrese M, et al. Peyronie’s disease: Prevalence and association with cigarette smoking. A multicenter
population- based study in men aged 50-69 years. Eur Urol. 2001;40:525-530.
DOI: https://doi.org/10.1159/000049830
DiBenedetti DB, Nguyen D, Zografos L, et al. A Population-Based Study of Peyronie’s Disease: Prevalence and Treatment Patterns in the United States. Adv Urol. 2011; 2011:282503.
DOI: https://doi.org/10.1155/2011/282503
Shiraishi K, Shimabukuro T, Matsuyama H. The prevalence of Peyronie’s disease in Japan: A study in men undergoing maintenance hemodialysis and routine health checks. J Sex Med. 2012; 9:2716-2723.
DOI: https://doi.org/10.1111/j.1743-6109.2012.02868.x
Stuntz M, Perlaky A, des Vignes F, et al. The Prevalence of Peyronie’s Disease in the United States: A Population-Based Study. PLoS ONE 2016; 11:e0150157.
DOI: https://doi.org/10.1371/journal.pone.0150157
Kyei MY, Mensah JE, Asante E, et al. Peyronie’s Disease in People of African Origin: A Mini Review. J Ger Ag Res. 2017;1:104.
Levine LA, Estrada CR, Storm DW, et al. Peyronie disease in younger men: characteristics and treatment results. J Androl. 2003;24:27-32.
DOI: https://doi.org/10.1002/j.1939-4640.2003.tb02634.x
Cilio S, Fallara G, Capogrosso P, et al. The symptomatic burden of Peyronie's disease at presentation according to patient age: A critical analysis of the Peyronie's disease questionnaire (PDQ) domains. Andrology 2023; 11:501-507.
DOI: https://doi.org/10.1111/andr.13352
Paulis G, De Giorgio G, Paulis A. Clinical Presentation of Peyronie's Disease: A Retrospective Study of 564 Cases. Diagnostics (Basel) 2024; 14:1125.
DOI: https://doi.org/10.3390/diagnostics14111125
Weidner W, Schroeder-Printzen I, Weiske WH, et al. Sexual dysfunction in Peyronie’s disease: An analysis of 222 patients without previous local plaque therapy. J Urol. 1997; 157:325-328.
DOI: https://doi.org/10.1016/S0022-5347(01)65370-9
Nelson CJ, Diblasio C, Kendirci M, et al. The chronology of depression and distress in men with Peyronie’s disease. J Sex Med. 2008; 5:1985-1990.
DOI: https://doi.org/10.1111/j.1743-6109.2008.00895.x
Devine CJ Jr, Somers KD, Ladaga LE. Peyronie’s disease: Pathophysiology. Prog Clin Biol Res. 1991; 370:355-358.
Devine CJJ, Somers KD, Jordan GH, et al. Proposal: Trauma as a cause of Peyronie’s lesion. J Urol. 1997; 157:285-290.
DOI: https://doi.org/10.1016/S0022-5347(01)65361-8
Jarow JP, Lowe FC. Penile trauma: An etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol. 1997; 158:1388-1390.
DOI: https://doi.org/10.1016/S0022-5347(01)64222-8
Somers KD, Dawson DM. Fibrin deposition in Peyronie’s disease plaque. J Urol. 1997, 157, 311-315.
DOI: https://doi.org/10.1016/S0022-5347(01)65367-9
Moreland RB, Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res. 2002; 14:406-410.
DOI: https://doi.org/10.1038/sj.ijir.3900875
Sikka SC, Hellstrom WJ. Role of oxidative stress and antioxidants in Peyronie’s disease. Int J Impot Res. 2002;14:353-360.
DOI: https://doi.org/10.1038/sj.ijir.3900880
Bivalacqua TJ, Champion HC, Hellstrom WJ. Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie’s disease. Int J Impot Res. 2002; 14:345-352.
DOI: https://doi.org/10.1038/sj.ijir.3900872
El-Sakka AI, Salabas E, Dinçer M, et al. The pathophysiology of Peyronie’s disease. Arab J Urol. 2013; 11:272-277.
DOI: https://doi.org/10.1016/j.aju.2013.06.006
Paulis G, De Giorgio G, Paulis L. Role of Oxidative Stress in Peyronie’s Disease: Biochemical Evidence and Experiences of Treatment with Antioxidants. Int J Mol Sci. 2022, 23, 15969.
DOI: https://doi.org/10.3390/ijms232415969
Jalkut, M, Gonzalez-Cadavid, N, Rajfer, J. Peyronie's Disease: A Review. Rev. Urol. 2003; 5:142-148.
DOI: https://doi.org/10.1007/s11934-004-0074-y
Kadioglu A, Akman T, Sanli O, et al. Surgical Treatment of Peyronie’s Disease: A Critical Analysis. Eur Urol. 2006; 50:235-248.
DOI: https://doi.org/10.1016/j.eururo.2006.04.030
Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol. 2006; 175:2115-2118.
DOI: https://doi.org/10.1016/S0022-5347(06)00270-9
Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med. 2010; 7:2359-2374.
DOI: https://doi.org/10.1111/j.1743-6109.2010.01850.x
Levine LA, Burnett AL. Standard operating procedures for Peyronie’s disease. J Sex Med. 2013, 10, 230-244.
DOI: https://doi.org/10.1111/j.1743-6109.2012.03003.x
Garaffa G, Trost LW, Serefoglu EC, et al. Understanding the course of Peyronie's disease. Int J Clin Pract. 2013; 67:781-788.
DOI: https://doi.org/10.1111/ijcp.12129
Paulis G, Cavallini G. Clinical evaluation of natural history of Peyronie's disease: our experience, old myths and new certainties. Inflamm Allergy Drug Targets. 2013; 12:341-348.
DOI: https://doi.org/10.2174/18715281113129990055
Bella AJ, Lee JC, Grober ED, et al. 2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile
curvature. Can Urol Assoc J. 2018;12:E197-E209.
DOI: https://doi.org/10.5489/cuaj.5255
Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU guidelines on penile curvature. Eur Urol. 2012; 62:543-552.
DOI: https://doi.org/10.1016/j.eururo.2012.05.040
Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie's Disease: AUA Guideline. J Urol. 2015; 194:745-753.
DOI: https://doi.org/10.1016/j.juro.2015.05.098
Levine LA, Larsen S. Diagnosis and Management of Peyronie Disease. In: Campbell-Walsh Urology. 11th Ed., Wein AJ, Kavoussi LR, Partin AW, Peters CA, Eds,; Elsevier Saunders: Philadelphia (PA), 2015. Volume 1 (Chapter 31); 722-748.
Kendirci M, Hellstrom WJ. Critical analysis of surgery for Peyronie's disease. Curr Opin Urol. 2004; 14:381-388.
DOI: https://doi.org/10.1097/00042307-200411000-00015
Paulis G, Brancato T, D'Ascenzo R, et al. Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology 2013; 1:120-128.
DOI: https://doi.org/10.1111/j.2047-2927.2012.00007.x
Chung E, Ralph D, Kagioglu A, et al. Evidence-based management guidelines on Peyronie’s disease. J Sex Med. 2016; 13:905-923.
DOI: https://doi.org/10.1016/j.jsxm.2016.04.062
Gennaro R, Barletta D, Paulis G. Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease. Int Urol Nephrol. 2015; 47:1595-1602.
DOI: https://doi.org/10.1007/s11255-015-1074-1
Zucchi A, Costantini E, Cai T, et al. Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease:
Preliminary Results From a Prospective, Multicenter, Pilot Study. Sex Med. 2016; 4: e83-e88.
Nguyen HNT, Anaissie J, DeLay KJ, et al. Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie’s disease. J Sex Med. 2017; 14:1220-1225.
DOI: https://doi.org/10.1016/j.jsxm.2017.08.008
Cilio S, Rocca R, Celentano G, et al. Intraplaque injections of hyaluronic acid for the treatment of stable-phase Peyronie's disease: a retrospective single-center experience. Asian J Androl. 2024;26:268-271.
DOI: https://doi.org/10.4103/aja202371
Osmonov D, Ragheb A, Ward S, et al. ESSM Position Statement on Surgical Treatment of Peyronie's Disease. Sex Med. 2022; 10:100459.
DOI: https://doi.org/10.1016/j.esxm.2021.100459
Kelâmi A. Autophotography in evaluation of functional penile disorders. Urology 1983; 21:628-629.
DOI: https://doi.org/10.1016/0090-4295(83)90210-8
Eri LM, Thomassen H, Brennhovd B, et al. Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. Prostate Cancer Prostatic Dis. 2002; 5:273-278.
DOI: https://doi.org/10.1038/sj.pcan.4500568
Lee JS, Chung BH. Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume as compared with radical prostatectomy specimens. Urol Int. 2007; 78:323-327.
DOI: https://doi.org/10.1159/000100836
Kahl C, Cleland JA. Visual analogue scale, numeric pain rating scale and the McGill pain Questionnaire: An overview of psychometric properties. Phys Ther Rev. 2005; 10:123-128.
DOI: https://doi.org/10.1179/108331905X55776
Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49:822-830.
DOI: https://doi.org/10.1016/S0090-4295(97)00238-0
Hellstrom WJ, Feldman R, Rosen RC, et al. Bother and distress associated with Peyronie's disease: validation of the Peyronie's disease questionnaire. J Urol. 2013, 190, 627-634.
DOI: https://doi.org/10.1016/j.juro.2013.01.090
Paulis G, De Giorgio G. Complete Plaque Regression in Patients with Peyronie’s Disease After Multimodal Treatment with Antioxidants. A Report of 2 Cases. Am J Case Rep. 2022;23:e936146.
DOI: https://doi.org/10.12659/AJCR.936146
Paulis G, De Giorgio G. Full Regression of Peyronie’s Disease Plaque Following Combined Antioxidant Treatment: A Three-Case Report. Antioxidants 2022; 11:1661.
DOI: https://doi.org/10.3390/antiox11091661
Paulis G, De Giorgio G. Patients with Peyronie’s disease achieve complete plaque regression after multimodal treatment with antioxidants: A case series. J Med Case Rep. 2022; 16:359.
DOI: https://doi.org/10.1186/s13256-022-03614-1
Paulis G, De Giorgio G. Disappearance of Plaque Following Treatment with Antioxidants in Peyronie's Disease Patients-A Report of 3 Cases. Clin Pract. 2022; 12:1020-1033.
DOI: https://doi.org/10.3390/clinpract12060105
Kwon KD, Choi MJ, Park, JM, et al. Silencing histone deacetylase 2 using small hairpin RNA induces regression of fibrotic plaque in a rat model of Peyronie’s disease. BJU Int. 2014; 114:926-936.
DOI: https://doi.org/10.1111/bju.12812
Song KM, Chung DY, Choi MJ, et al. Vactosertib, a Novel, Orally Bioavailable Activin Receptor-Like Kinase 5 Inhibitor, Promotes Regression of Fibrotic Plaques in a Rat Model of Peyronie's Disease. World J Mens Health. 2020; 38:552-563.
DOI: https://doi.org/10.5534/wjmh.190071
Ryu JK, Piao S, Shin HY, et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med. 2009;6:1284-1296.
DOI: https://doi.org/10.1111/j.1743-6109.2009.01216.x
Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol. 1990; 144:1376-1379.
DOI: https://doi.org/10.1016/S0022-5347(17)39746-X
Kadioglu A, Tefekli A, Erol B, et al. A retrospective review of 307 men with Peyronie's disease. J. Urol. 2002;168:1075-1079.
DOI: https://doi.org/10.1016/S0022-5347(05)64578-8
Weidner W, Hauck EW, Schnitker J, Peyronie's Disease Study Group. Potassium paraaminobenzoate (POTABA™) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005; 47:530-536.
DOI: https://doi.org/10.1016/j.eururo.2004.12.022
Bekos A, Arvaniti M, Hatzimouratidis K, et al. The natural history of Peyronie's disease: an ultrasonography-based study. Eur. Urol. 2008; 53:644-650.
DOI: https://doi.org/10.1016/j.eururo.2007.07.013
Levine LA. Peyronie's disease: contemporary review of non-surgical treatment. Transl Androl Urol. 2013; 2:39-44.
DOI: https://doi.org/10.1016/j.aju.2013.03.008
Paulis G, D'Ascenzo R, Nupieri P, et al. Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases. Int J Androl. 2012; 35:521-527.
DOI: https://doi.org/10.1111/j.1365-2605.2011.01219.x
Paulis G, Cavallini G, De Giorgio G, et al. Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie’s disease (chronic inflammation of the tunica albuginea). Results of a controlled study. Inflamm Allergy Drug Targets 2013; 12:403-409.
DOI: https://doi.org/10.2174/1871528112666131205112432
Paulis G, Barletta D, Turchi P, et al. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie’s disease: A case-control study. Res Rep Urol. 2016; 8:1-10.
DOI: https://doi.org/10.2147/RRU.S97194
Tang YZ, Liu ZQ. Evaluation of the free-radical-scavenging activity of diclofenac acid on the free-radical-induced haemolysis of human erythrocytes. J. Pharm Pharmacol. 2006; 58:625-631.
DOI: https://doi.org/10.1211/jpp.58.5.0007
Radermacher J, Jentsch D, Scholl MA, et al. Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol. 1991; 31:537-541.
DOI: https://doi.org/10.1111/j.1365-2125.1991.tb05576.x
Paulis G, De Giorgio G, Paulis A. Ultrasound Elastography as a Diagnostic Tool for Peyronie's Disease: A State-of-the-Art Review. Diagnostics (Basel) 2024; 14:665.
DOI: https://doi.org/10.3390/diagnostics14060665
Traunero F, Di Grazia M. Ongaro,L, et al. Validation of the Italian version of the Peyronie’s Disease Questionnaire (PDQ). Int J Impot Res 2024;36:588-591.
DOI: https://doi.org/10.1038/s41443-023-00792-4
Gallo L, Sarnacchiaro P. Ten-year experience with multimodal treatment for acute phase Peyronie’s disease: A real life clinical report. Actas Urol Esp. (Engl Ed). 2019; 43:182-189.
DOI: https://doi.org/10.1016/j.acuroe.2019.03.007
Favilla V, Russo GI, Privitera S, et al. Combination of intralesional verapamil and oral antioxidants for Peyronie’s disease: A prospective, randomised controlled study. Andrologia 2014; 46:936-942.
DOI: https://doi.org/10.1111/and.12178
Riedl CR, Sternig P, Gallé G, et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: A randomized placebo-controlled double-blind prospective clinical study. Eur Urol. 2005; 48:656-661.
DOI: https://doi.org/10.1016/j.eururo.2005.04.011
Alizadeh M, Karimi F, Fallah, MR. Evaluation of verapamil efficacy in Peyronie’s disease comparing with pentoxifylline. Glob J Health Sci. 2014; 6:23-30.
DOI: https://doi.org/10.5539/gjhs.v6n7p23
Carillon J, Rouanet JM, Cristol JP, Brion, R. Superoxide dismutase administration, a potential therapy against oxidative stress related diseases: several routes of supplementation and proposal of an original mechanism of action. Pharm Res. 2013; 30:2718-2728.
DOI: https://doi.org/10.1007/s11095-013-1113-5
McCauley JF, Dean RC. Diagnostic utility of penile ultrasound in Peyronie’s disease. World J Urol. 2020; 38:263-268.
DOI: https://doi.org/10.1007/s00345-019-02928-y
Parmar M, Masterson JM, Masterson, TA, 3rd. The role of imaging in the diagnosis and management of Peyronie’s disease. Curr Opin Urol. 2020; 30:283-289.
DOI: https://doi.org/10.1097/MOU.0000000000000754
How to Cite
Paulis, G., De Giorgio, G., & Paulis, A. (2024). Healing of Peyronie’s disease after multimodal antioxidant treatment. A case series. Archivio Italiano Di Urologia E Andrologia. https://doi.org/10.4081/aiua.2024.12956
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.